As mentioned previously, activation of GSK3β has been mentioned in various NDs and several GSK3β inhibitors have entered testing in clinical trials related to AD and ALS (Choi et al. 2020). This evidence concerns the gene GSK3B and amyotrophic lateral sclerosis.